ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

ICU Medical, Inc.

BEBIG Medical GmbH provides products and services related to prostate and ophthalmic brachytherapy, as well as HDR brachytherapy and X-ray therapy.

BEBIG Medical GmbH

Nanospectra Biosciences is a medical device company pioneering a patient-centric use of nanomedicine for selective thermal ablation.

Nanospectra Biosciences

ICU Medical is focused on providing IV therapy products and technologies that help safely and efficiently meet patient care challenges.

Metric
Company Name	ICU Medical, Inc.	BEBIG Medical GmbH	Nanospectra Biosciences
Symbol	ICUI
MSH ID	COM:ICUMED	COM:BEBIG	COM:NANOSPECTRA
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Instruments & Supplies	Medical Devices	Medical Devices
Country	US	DE	US
Stage			Venture Round
Employee Count	14K
Website	icumed.com	bebig.com	nanospectra.com
LinkedIn
Founders

Metric
Market Cap	3.00B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital		6.07M

Metric
Revenue	2.26B
Revenue (LTM)
Revenue (NTM)
Gross Profit	709.82M
EBITDA	290.37M
Operating Income	39.69M
Net Income	-29.66M
EPS	-1.23
Diluted EPS	-1.23
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.32
Operating Profit Margin	0.01
EBITDA Margin	0.13
Net Profit Margin	-0.01
Return on Equity	-0.01
Return on Assets	-0.01
Return on Capital Employed	0.01

COM:ICUMED

ICU Medical

Last Close

168.84

22/11 21:00

Market Cap

3.00B

Beta: -

Volume Today

249.03K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-74.93
P/B Ratio	1.00
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.95
EV Multiple	13.73

Metric
Days Sales Outstanding	26.26
Days Payables Outstanding	36.18
Days Inventory Outstanding	168.88
Operating Cycle	195.42
Cash Conversion Cycle	159.71
Asset Turnover	0.54

Metric
Operating Cash Flow	166.20M
Free Cash Flow	72.53M
Cash Flow to Debt	0.16
Operating Cash Flow/Sales	0.11
Free Cash Flow Yield	-0.01

Metric
Cash & Equivalents	254.22M
Accounts Receivable	48.63M
Inventory	709.36M
Goodwill	1.47B
Debt to Capitalization	0.45
Debt to Assets	0.37
Current Ratio	2.63
Quick Ratio	1.42

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02
R&D to Revenue	0.04
SG&A to Revenue